We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Read MoreHide Full Article
Key Takeaways
Rocket Pharmaceuticals reported Q2 EPS of $1.08 in contrast to year-ago loss of 62 cents per share.
Kresladi launch preparations are underway, with patient onboarding set to begin in Q4 2026.
RP-A501 showed positive initial safety findings, with an FDA regulatory pathway update expected in 2H 2026.
Rocket Pharmaceuticals (RCKT - Free Report) reported earnings of $1.08 per share (including certain one-time items) in the second quarter of 2026 in contrast to a loss of 62 cents per share incurred in the year-ago quarter. The Zacks Consensus Estimate for the company’s bottom line was earnings of 28 cents per share.
Excluding these one-time items, the company reported a loss of 40 cents per share in the second quarter of 2026.
Rocket Pharmaceuticals did not record any revenues in the second quarter of 2026. However, the Zacks Consensus Estimate for the company’s top line was $1 million.
Year to date, shares of Rocket Pharmaceuticals have risen 3.7% compared with the industry’s increase of 6.1%.
Image Source: Zacks Investment Research
RCKT’s Q2 Results in Detail
In the reported quarter, general and administrative expenses declined by around 30.4% year over year to $17.4 million, owing to lower legal expenses and other expenses.
Research and development expenses were $29.5 million, down 30.9% from the year-ago quarter’s figure. The decrease was primarily driven by lower manufacturing and development costs and certain other costs.
As of June 30, 2026, Rocket Pharmaceuticals had cash, cash equivalents and investments of $283.7 million compared with $144.4 million as of March 31, 2026. Management noted that the company’s current cash position reflects the proceeds from the sale of the Rare Pediatric Disease Priority Review Voucher.
RCKT’s Recent Key Updates
In March 2026, the FDA granted accelerated approval to RCKT’s gene therapy Kresladi (marnetegragene autotemcel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare genetic disorder.
Following the nod, Kresladi became the first gene therapy to be approved by the FDA for treating children with severe LAD-I due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplant.
Per the company, launch preparations for Kresladi are underway, and patient onboarding is beginning in the fourth quarter of 2026.
Rocket Pharmaceuticals is also developing an investigational gene therapy candidate, RP-A501, in a phase II study for treating patients with Danon disease. RP-A501 is the most advanced AAV-based candidate in the company’s pipeline.
Earlier this month, the company announced positive initial safety findings from the first three patients treated with RP-A501 under a modified Phase 2 protocol for Danon disease. The patients received a recalibrated dose of RP-A501 (3.8 x 10¹³ GC/kg) with a refined immunomodulatory regimen, and no cases of thrombotic microangiopathy, capillary leak syndrome or other significant safety concerns were observed. RCKT is engaging with the FDA to determine the pathway for dosing additional patients and completing the pivotal phase II study, with an update on the regulatory pathway expected in the second half of 2026.
Rocket Pharmaceuticals is also developing RP-A601 in an early-stage study for treating arrhythmogenic cardiomyopathy. The company also plans to start initial patient dosing in a phase I study evaluating another gene therapy candidate, RP-A701, for the treatment of dilated cardiomyopathy in the second half of 2026.
Rocket Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 0.4% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 163.9% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.
View the Zacks #1 Rank List
Image: Bigstock
Rocket Pharmaceuticals Q2 Earnings Rise Y/Y, Kresladi Launch in Focus
Key Takeaways
Rocket Pharmaceuticals (RCKT - Free Report) reported earnings of $1.08 per share (including certain one-time items) in the second quarter of 2026 in contrast to a loss of 62 cents per share incurred in the year-ago quarter. The Zacks Consensus Estimate for the company’s bottom line was earnings of 28 cents per share.
Excluding these one-time items, the company reported a loss of 40 cents per share in the second quarter of 2026.
Rocket Pharmaceuticals did not record any revenues in the second quarter of 2026. However, the Zacks Consensus Estimate for the company’s top line was $1 million.
Year to date, shares of Rocket Pharmaceuticals have risen 3.7% compared with the industry’s increase of 6.1%.
Image Source: Zacks Investment Research
RCKT’s Q2 Results in Detail
In the reported quarter, general and administrative expenses declined by around 30.4% year over year to $17.4 million, owing to lower legal expenses and other expenses.
Research and development expenses were $29.5 million, down 30.9% from the year-ago quarter’s figure. The decrease was primarily driven by lower manufacturing and development costs and certain other costs.
As of June 30, 2026, Rocket Pharmaceuticals had cash, cash equivalents and investments of $283.7 million compared with $144.4 million as of March 31, 2026. Management noted that the company’s current cash position reflects the proceeds from the sale of the Rare Pediatric Disease Priority Review Voucher.
RCKT’s Recent Key Updates
In March 2026, the FDA granted accelerated approval to RCKT’s gene therapy Kresladi (marnetegragene autotemcel) to treat patients with severe leukocyte adhesion deficiency-I (LAD-I), an ultra-rare genetic disorder.
Following the nod, Kresladi became the first gene therapy to be approved by the FDA for treating children with severe LAD-I due to biallelic variants in ITGB2 without an available human leukocyte antigen-matched sibling donor for allogeneic hematopoietic stem cell transplant.
Per the company, launch preparations for Kresladi are underway, and patient onboarding is beginning in the fourth quarter of 2026.
Rocket Pharmaceuticals is also developing an investigational gene therapy candidate, RP-A501, in a phase II study for treating patients with Danon disease. RP-A501 is the most advanced AAV-based candidate in the company’s pipeline.
Earlier this month, the company announced positive initial safety findings from the first three patients treated with RP-A501 under a modified Phase 2 protocol for Danon disease. The patients received a recalibrated dose of RP-A501 (3.8 x 10¹³ GC/kg) with a refined immunomodulatory regimen, and no cases of thrombotic microangiopathy, capillary leak syndrome or other significant safety concerns were observed. RCKT is engaging with the FDA to determine the pathway for dosing additional patients and completing the pivotal phase II study, with an update on the regulatory pathway expected in the second half of 2026.
Rocket Pharmaceuticals is also developing RP-A601 in an early-stage study for treating arrhythmogenic cardiomyopathy. The company also plans to start initial patient dosing in a phase I study evaluating another gene therapy candidate, RP-A701, for the treatment of dilated cardiomyopathy in the second half of 2026.
Rocket Pharmaceuticals, Inc. Price, Consensus and EPS Surprise
Rocket Pharmaceuticals, Inc. price-consensus-eps-surprise-chart | Rocket Pharmaceuticals, Inc. Quote
RCKT's Zacks Rank & Stocks to Consider
Rocket Pharmaceuticals currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Repligen (RGEN - Free Report) and Liquidia Corporation (LQDA - Free Report) , each currently sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the past 60 days, estimates for Repligen’s 2026 earnings per share have risen from $1.99 to $2.06, while estimates for 2027 have increased from $2.57 to $2.62 during the same time. RGEN shares have declined 0.4% year to date.
Repligen’s earnings beat estimates in each of the trailing four quarters, with the average surprise being 16.80%.
Over the past 60 days, estimates for Liquidia’s 2026 earnings per share have risen from $2.97 to $3.02, while estimates for 2027 have increased from $4.81 to $5.31 during the same time. LQDA shares have surged 163.9% year to date.
Liquidia’s earnings beat estimates in three of the trailing four quarters, while missing the same on the remaining occasion, with the average surprise being 54.40%.